Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial

1. Curtis, J.R.
2. Yamaoka, K.
3. Chen, Y.-H.
4. Bhatt, D.L.
5. Gunay, L.M.
6. Sugiyama, N.
7. Connell, C.A.
8. Wang, C.
9. Wu, J.
10. Menon, S.
11. Vranic, I.
12. Gómez-Reino, J.J.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1136/ARD-2022-222543 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus